Sun Pharmaceutical Industries faced a decline in shares after the US District Court of New Jersey issued a preliminary injunction preventing the company from launching its drug ‘LEQSELVI’ for severe alopecia areata treatment. The injunction will hold until a favorable court ruling or the expiration of the relevant patent.
The injunction follows Sun Pharma’s challenge filed on August 1. Following the court’s decision, Sun Pharma’s shares were down 3.38%, trading at ₹1,795.60 on NSE as of 9:16 am.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
